CMS successfully signed an Exclusive Distribution Agreement of Maltofer? and Uro-Vaxom? for China with Vifor Pharma

Company News

China Medical System Holdings Limited (“CMS”) signed an Exclusive Distribution Agreement (the “Agreement”) with Vifor Pharma for its products Maltofer® (iron polymaltose complex) and Uro-Vaxom® (an extract of 18 strains of the bacterium Escherichia coli) in the Chinese market (excluding Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan) on 20 December 2012.

According to the Agreement, CMS gained exclusive distribution rights of the 2 products from Vifor Pharma in China. At the same time, Vifor Pharma has authorized CMS to take full responsibility of registration affairs of the products in China. The initial term of the Agreement shall be 10 years from the date of first commercialisation of the products in China, and shall be automatically extended for a further 5 years if CMS achieves the minimum sales target defined in the Agreement.

Maltofer® is an oral iron supplement developed by Vifor Pharma for the treatment of iron deficiency (“ID”) without anemia and iron deficiency anemia (“IDA”), which has been marketed globally in more than 80 countries. Formulations of Maltofer® to be introduced in China include tablets and syrup, which can meet the needs of different patients. Uro-Vaxom® is used for the treatment and prevention of recurrent urinary tract infections (“UTIs”), it stimulates the immune system and the body’s natural defense against urinary pathogens.

At present, there is no product containing the same ingredients as Maltofer® and Uro-Vaxom® in the China market, the market potential is huge.